怎么买地拉罗司呢？

A prospective, observational study in my country using the liver, pancreas, and heart as monitoring indicators confirmed that (Deferasirox) improved organ function in patients with iron overload. The results of the TELESTO study released at ASH2018 also proved that Deferasirox continuously reduces serum ferritin levels, while reducing the risk of heart function damage, liver function damage, and transformation to leukemia by 36.4%. In summary, Deferasirox is easy to administer, can significantly reduce ferritin levels, and has a definite effect in protecting important target organ systems such as the liver, heart, and endocrine system. It is currently the preferred option for iron removal treatment. Today we will take a look at how to buy deferasirox?

Deferasirox should be taken once daily on an empty stomach, at least 30 minutes before a meal, preferably at the same time each day. Tablets should not be chewed or swallowed whole. Deferasirox should not be taken with aluminum-containing antacids, and the dose (mg/kg) needs to be calculated and rounded to the nearest whole tablet. Completely dissolve the tablets in water, apple juice or orange juice (100-200mL) by stirring until a clear suspension is obtained and then drink it. The remaining medicine must be added with a small amount of water, apple juice or orange juice and mixed well before taking. Not recommended for dissolution in carbonated drinks or milk as it can cause foaming and slow dispersion.

Deferasirox is currently the only oral iron chelator developed by Novartis. It was approved by the FDA in November 2005 for use in patients 2 years and older with chronic iron overload caused by blood transfusions. In December 2012, Deferasirox was approved by the European Commission for the treatment of chronic iron overload in patients aged 10 years and older with non-transfusion-dependent thalassemia (NTDT) syndrome who require chelation therapy due to contraindications or insufficiency of deferoxamine mesylate therapy. On January 23, 2013, the FDA approved a new indication for deferasirox for the treatment of chronic iron overload in patients aged 10 years and older with non-transfusion-dependent thalassemia (NTDT).

Since Deferasirox has been approved for marketing in my country, patients can purchase Deferasirox at large domestic hospitals or pharmacies with a prescription. The only drawback is that the price is relatively high. If the patient chooses the highly cost-effective Indian Deferasirox, in addition to going to India in person, he can also obtain it through domestic professional overseas medical service institutions.

The above is what I purchased, I hope it can help you!